$99 device makes pump and CGM data viewable to Android smartphone users. Plus, a first look at cool pattern recognition in the Sugar.IQ app with IBM Watson

The artificial pancreas is here for those willing to build their own; what can manufacturers learn from OpenAPS?

Tighter requirements for home meters. What does this mean for current and future blood glucose monitors?

Strong results from the IMPACT study in low-A1c users.

Six systems expected by 2019, plus an FAQ! Which system is right for me?

Ginger Vieira and Jennifer Smith’s month-to-month guide for managing blood sugars, nutrition, exercise, and mental health during pregnancy

“Adam, what do you eat when you’re on a plane?” My six go-to strategies from hundreds of flights and airports

The lame food advice at Adam Brown's diagnosis, why it didn’t work, and Adam's #1 Bright Spot solution

Expected in 2017. Plus, the latest in the pipeline, including concentrated insulin systems and the Horizon Automated Glucose Control System

A six-week study of Tandem’s first automated insulin delivery device with Dexcom’s G5 CGM

A workshop hosted by the JDRF and Helmsley Charitable Trust brought together leaders in the field to discuss opportunities and advances in the treatment and possible...

First trial next month, launch expected in 2-3 years; Dexcom CGM included; a big commitment to diabetes tech innovation from an insulin company

The diaTribe Foundation and TCOYD host discussion at ADA focusing on access, outcomes beyond A1c, and future expectations

How it works and why it could help with exercise challenges. Plus, how diaTribe readers can try it for free

A recent trial comparing once-weekly GLP-1 agonists semaglutide and Trulicity found improved A1c and double the weight loss with semaglutide

Comparing Medtronic’s MiniMed 670G to injections and pumps in people with type 1 diabetes, with and without CGM; enrollment to open in May at some trial locations

What does donated diabetes data tell us about time-in-range across different age groups?

A currently-enrolling trial is investigating a new arthritis medication along with type 2 diabetes drug Victoza, aiming to preserve insulin production in people with...

The FDA decision on Novo Nordisk’s basal insulin is based on positive safety and efficacy data of Tresiba versus other basal insulins

Trial results testing sotagliflozin and Farxiga in type 1 diabetes show greater A1c lowering and weight loss, plus continued conversation about small risk of DKA